TABLE 1.
Clinical Outcomes of PIOL Patients
| Initial Therapy
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (y) | Country | CNS Involvement | Radiation | MTX | Other Chemotherapy |
Relapse | Subsequent Treatment |
Survival (mo) | bcl-2 t(14; 18) Translocation |
| 1 | 76 | France | + | − | + (systemic) | − | − | N/A | 1 | + |
| 2 | 63 | United States | − | − | + (intravitreal) | − | + | Intrathecal: MTX | 56+ | + |
| 3 | 60 | Puerto Rico | + | + | − | − | − | Intravitreal: MTX N/A | 6 | + |
| 4 | 69 | Japan | + | + (30 Gy) | − | + Systemic: CHOP | + | Radiation: 40 Gy | 19 | + |
| 5 | 46 | Brazil | + | + (10 Gy) | − | − | − | N/A | 64+ | + |
| 6 | 51 | United States | + | − | + (intrathecal) | + Systemic: dexamethasone; Intrathecal: Ara-C | + | Systemic: BCNU, cisplatin, temozolomide, Ara-C Intrathecal: MTX, BCNU Intravitreal: MTX | 67+ | + |
| 7 | 77 | Japan | − | + (30 Gy) | − | − | − | N/A | 11+ | − |
| 8 | 63 | Japan | − | + (26 Gy) | − | − | − | N/A | 19+ | − |
| 9 | 80 | Japan | − | + (35 Gy) | − | − | − | N/A | 23+ | + |
| 10 | 48 | United States | + | + (54 Gy) | + (intrathecal) | + Systemic: Promace/ Cytabom Intrathecal: Ara-C | + | None | 9 | + |
| 11 | 73 | Japan | − | + (30 Gy) | − | + Systemic: CHOP | − | N/A | 34+ | − |
| 12 | 80 | Japan | − | + (39 Gy) | − | − | − | N/A | 48+ | + |
| 13 | 40 | Israel | + | U | U | U | U | U | 20+ | + |
| 14 | 38 | United States | + | + (40 Gy) | + (systemic high dose; intravitreal) | + | + | Systemic: MTX, stem cell transplantation; Radiation: dose unknown; Intravitreal: MTX | 29+ | + |
| 15 | 67 | United States | − | − | + (systemic high dose) | − | − | N/A | 12+ | + |
| 16 | 57 | United States | − | − | + (systemic high dose; intrathecal) | + Systemic: vincristine, procarbazine | + | Radiation: dose unknown Intravitreal: MTX | 33+ | + |
| 17 | 78 | United States | + | + (45 Gy) | U | U | U | U | 5+ | − |
| 18 | 58 | United States | + | − | + (systemic high dose) | + Systemic: thiotepa, vincristine Intrathecal: Ara-C) | + | Systemic: MTX Intrathecal: MTX, Ara-C Radiation × 2: 30 and 49 Gy | 84+ | + |
| 19 | 79 | United States | + | + (60 Gy) | − | − | + | None | 33+ | − |
| 20 | 47 | India | + | + (45 Gy) | + (systemic high dose) | + Systemic vincristine, thiotepa, dexamethasone, Intrathecal: Ara-C | + | Systemic: thiotepa, vincristine, MTX, dexamethasone, bone marrow transplantation Intrathecal: MTX and Ara-C | 67+ | + |
| 21 | 74 | United States | + | + (unknown dose) | − | − | + | none | 12+ | − |
| 22 | 73 | United States | − | − | − | − | − | N/A | 8 | − |
| 23 | 57 | Canada | + | − | + (systemic high dose) | − | − | N/A | 6+ | + |
U, information unavailable; MTX, methotrexate; N/A, not applicable.